Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

ADVANZ PHARMA CORP LTD Common Stock · CXRXF

CXRXFOTCCommon stockHistorical · closed Jun 11, 2021CIK 1642271Updated Nov 16, 2026

Company: ADVANZ PHARMA Corp. →

Name history
Concordia International Corp. · through Nov 29, 2018Concordia Healthcare Corp. · through Jun 20, 2016

CXRXF price & chart

Provider market data
Historical security

This listing closed Jun 11, 2021. Live provider charts are shown only for current listings.

In the news

No coverage from other publishers is available.

Recent filings

No filing activity has been returned.

Financials

FY 2017 · USD
Revenue626,169,000USD · FY 2017
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

Net income-1,590,735,000USD · FY 2017
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

Assets—USD · FY 2017
Cash— · FY 2017
Operating income-1,164,948,000USD · FY 2017
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

Diluted EPS-31.1USD per share · FY 2017
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemFY 2017FY 2016
Cash flows from financing activities:
Dividends paid—
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

—
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

Additional Financial Items
AdjustmentsForIncomeTaxExpenseUSD-36,757,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

-34,801,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

AdjustmentsForSharebasedPaymentsUSD8,711,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

30,753,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD-72,891,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

128,574,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

DividendsPaidClassifiedAsFinancingActivitiesUSD0
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

11,477,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

GeneralAndAdministrativeExpenseUSD50,690,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

56,455,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

GoodwillUSD244,957,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

As of 2017-12-31

707,930,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

As of 2016-12-31

IncreaseDecreaseInWorkingCapitalUSD-42,440,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

-6,088,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

InterestPaidClassifiedAsFinancingActivitiesUSD294,297,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

251,734,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD0
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

350,000,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

ProceedsFromIssuingSharesUSD0
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

0
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD57,279,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

18,193,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2017FY 2016
Cost of Goods and Services Sold—
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

—
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

Total RevenueUSD626,169,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

816,159,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

Additional Financial Items
ApplicableTaxRatenumber0.27
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

0.27
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

BasicEarningsLossPerShareUSD per share-31.1
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

-25.79
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

CurrentTaxExpenseIncomeUSD18,491,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

36,846,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

DeferredTaxExpenseIncomeUSD-55,248,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

-71,647,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

DepreciationAndAmortisationExpenseUSD228,387,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

184,758,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

DilutedEarningsLossPerShareUSD per share-31.1
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

-25.79
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

EmployeeBenefitsExpenseUSD46,462,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

46,302,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD8,711,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

30,753,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

GeneralAndAdministrativeExpenseUSD50,690,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

56,455,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

GrossProfitUSD435,537,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

594,957,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD685,287,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

1,129,181,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossUSD1,194,765,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

1,132,243,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

IncomeTaxExpenseContinuingOperationsUSD-36,757,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

-34,801,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

ProfessionalFeesExpenseUSD51,441,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

41,899,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

ProfitLossAttributableToOwnersOfParentUSD-1,590,735,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

-1,315,694,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

ProfitLossBeforeTaxUSD-1,627,492,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

-1,348,894,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

ProfitLossFromOperatingActivitiesUSD-1,164,948,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

-942,307,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

ResearchAndDevelopmentExpenseUSD31,482,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

40,637,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

RevenueFromInterestUSD61,302,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2017-01-01 to 2017-12-31

21,671,000
Source

20-F · 2018-03-08 · 0001642271-18-000008

2016-01-01 to 2016-12-31

Lines labelled “Derived” are calculated from reported figures.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.